Harvey RD, Rubinstein WS, Ison G, et al. Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis. ASCO Annual Meeting 2019, abstract LBA108.
Perioperatief camrelizumab plus rivoceranib bij resectabel HCC met gemiddeld-hoog recidiefrisico
dec 2025 | Chirurgie, Maag-darm-leveroncologie